Product Description: Guselkumab is a recombinant human IgG1 monoclonal antibody against the IL-23p19 subunit. Guselkumab binds to human and cynomolgus monkey IL-23 with Kd values of 3.3 and 1.9 pmol/L, respectively. Guselkumab inhibits production of cytokines lying downstream of the IL-23 signaling pathway and can be used for psoriatic arthritis research[1].
Applications: COVID-19-immunoregulation
Formula: N/A
References: [1]International non-proprietary name: guselkumab Procedure No. EMEA/H/C/004271/0000par-public-assessment-report_en.pdf/[2]Li Li, et al. IBI112, a selective anti-IL23p19 monoclonal antibody, displays high efficacy in IL-23-induced psoriasiform dermatitis. Int Immunopharmacol
CAS Number: 1350289-85-8
Molecular Weight: N/A
Compound Purity: 98.97
Research Area: Inflammation/Immunology
Solubility: H2O
Target: Interleukin Related
English
Deutsch
